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Abstract 
Purpose: To conduct a retrospective, single institutional and comparative study for radical retropubic prostatectomy 
(RRP), high dose rate brachytherapy (HDRBT), cryoablation and high-intensity focused ultrasound (HIFU) in localized 
prostate cancer with respect to oncological and functional outcomes.
Methods: We reviewed 97, 161, 114 and 120 patients of RRP, HDRBT, cryoablation and HIFU respectively for localized 
prostate cancer from May 2008 to December 2013. PSA biochemical recurrence, salvage treatment-free rate, metasta-
sis-free rate, and biochemical recurrence-free survival were analyzed for oncological outcomes. Functional outcomes 
included complications and serial IIEF-5 scores, IPSS and related QoL scores.
Results: During nearly 3 years of follow-up, the patients of HDRBT experienced higher PSA biochemical recurrence 
rate overall (54.7%), as well as D’Amico intermediate-risk (34.4%) and high-risk (61.8%) groups, lower salvage treat-
ment-free rate (46.7%), and metastasis-free rate (90.7%). Besides, the patients of RRP demonstrated higher urethral 
stricture (29.9%) and urinary incontinence (11.3%). The patients of HIFU revealed lower de novo erectile dysfunction 
rate at 1 year (65.6%), higher serial IIEF-5 scores, lower IPSS and related QoL scores.
Conclusions: The patients of HDRBT demonstrated worse oncological outcomes in D’Amico intermediate and high-
risk groups. Besides, the patients of RRP had more complications rate in urethral stricture and urinary incontinence. 
Moreover, the patients of HIFU experienced better urinary function improvement and more possible sexual function 
preservation. In consideration of trifecta, HIFU may provide equivalent cancer control and better quality of life for 
patients of localized prostate cancer.
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Background
Trifecta, including urinary continence, potency and can-
cer control, is an important concept for treatment of 
localized prostate cancer in recent years (Bianco et  al. 
2005). It not only represents an ideal treatment outcome 
for localized prostate cancer, but implies the importance 
of the patients’ quality of life as well. Functional outcome 
cannot be overemphasized in comparison with oncologi-
cal outcome and may be the key concern for decision-
making of treatment modality, especially for prostate 
cancer. To date, radical prostatectomy, radiotherapy/
brachytherapy, cryoablation, and high-intensity focused 
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ultrasound are used to treat localized prostate cancer 
(National Comprehensive Cancer N 2014; Mottet et  al. 
2014). In fact, no single treatment modality has proven 
superior to the others, and the optimal treatment for 
localized prostate cancer remains a matter of debate.
To the best of our knowledge, there is a paucity of com-
parative studies regarding the outcomes of the four treat-
ments; therefore, we conducted a retrospective, single 
institutional and comparative study evaluating oncologi-
cal and functional outcomes of the four commonly used 
treatments for localized prostate cancer.
Methods
Patients and study design
This study was approved by the Chang Gung Medi-
cal Foundation Institutional Review Board (IRB) for 
data analysis, and the serial number is 100-1264B. The 
data were analyzed retrospectively and anonymously. 
From May 2008 to December 2013, patients with clini-
cally localized prostate cancer (T stage ≦T3a, N0, M0) 
were reviewed. The clinical stage is decided by Gleason 
score, digital rectal examination, initial prostate-specific 
antigen (iPSA), and image studies (bone scan, pelvic 
computed tomography or magnetic resonance imaging). 
Among these patients, we excluded the patients under-
going treatments other than the four treatment modali-
ties: (1) Radical retropubic prostatectomy (RRP), (2) High 
dose rate brachytherapy (HDRBT), (3) Cryoablation 
and (4) High-intensity focused ultrasound (HIFU). The 
non-randomized treatment selection was made by the 
surgeon and patient’s discussion and preference. Finally, 
there were four treatment groups: (1) RRP (N = 97), (2) 
HDRBT (N = 161), (3) Cryoablation (N = 114), and (4) 
HIFU (N = 120).
The perioperative parameters such as age, preoperative 
prostate volume, iPSA, Gleason score, T stage, D’Amico 
risk group, the 5-item version of the international index 
of erectile function (IIEF-5), international prostate symp-
tom score (IPSS) and related quality of life (QoL) score at 
baseline were collected for demographic data.
Besides, postoperative PSA nadir, time to PSA nadir, 
PSA biochemical recurrence (for radical retropubic 
prostatectomy, PSA  ≥  0.2  ng/mL; for the other three 
treatments, PSA ≥ PSA nadir + 2 ng/mL), salvage treat-
ment-free rate, and metastasis-free rate were checked for 
oncological outcomes.
In addition, we recorded urethral stricture, second 
transurethral resection of the prostate (TURP) or optic 
internal urethrotomy (OIU), urinary incontinence 
defined one or more daily absorbent pads use, epididymi-
tis, scrotal edema, rectal injury, irradiation cystitis, irra-
diation proctitis, series of IIEF-5, IPSS and related QoL 
scores at 6, 12, 18, and 24  months postoperatively for 
functional outcomes. Postoperative erectile dysfunction 
was defined by patients with preoperative IIEF-5  ≥  17 
and postoperative IIEF-5 < 17 (moderate to severe erec-
tile dysfunction) at 1 year.
Treatment techniques
Radical retropubic prostatectomy (RRP)
Radical retropubic prostatectomy was performed 
through a low midline incision and extraperitoneal 
approach. The extent of radical retropubic prostatectomy 
included the entire prostate gland, bilateral seminal vesi-
cles and pelvic lymph nodes. Neurovascular bundle spar-
ing technique was not intentionally used.
High dose rate brachytherapy (HDRBT)
High dose rate brachytherapy was first performed by 
urologists in conjunction with radiation oncologists. Irid-
ium radioisotopes (Ir192) were introduced by the radia-
tion oncologists through transperineal needles implanted 
by urologists in three fractions on two consecutive days. 
The dose rate was individually designed for each patient 
on the basis of the results of the examination of impor-
tant organs such as the urethra, bladder, and rectum, or 
any defect caused by TURP. The needles were removed 
after delivering the final HDR fraction. HDR brachy-
therapy (dose, 4–5.6  Gy per fraction) was performed 
as a boost followed by external beam radiation therapy 
(EBRT) (dose, 45–57.6 Gy) 2–3 weeks later. We did not 
give perioperative androgen deprivation therapy in all the 
patients (Chiang et al. 2004).
Cryoablation
Whole-gland cryoablation was performed by fourth-gen-
eration cryosurgical technology (Endocare Cryocare Sur-
gical System, Heathtronics Inc., Austin, TX, USA) under 
the guidance of transrectal ultrasonography with thermal 
sensor monitoring, urethral warming, and Denonvilliers’ 
fascia normal saline instillation to avoid urethral and rec-
tal injury (Liu et al. 2015).
High‑intensity focused ultrasound (HIFU)
Whole-gland HIFU was performed by Ablatherm® 
Integrated Imaging (EDAP TMS SA, Vaulx-en-Velin, 
France) under the guidance of transrectal ultrasonog-
raphy. In addition, all of the HIFU patients underwent 
transurethral resection of the prostate (TURP) before 
operation. If preoperative prostate volume was <30 mL, 
TURP and HIFU would be performed simultaneously. If 
preoperative prostate volume was ≥30 mL, HIFU would 
be performed 4 weeks later after TURP (Liu and Chiang 
2016).
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Statistical analysis
All the data was analyzed according to treatment types. 
Continuous variables were compared by one-way 
ANOVA test. Categorical variables were compared by 
Chi square test. Survival analysis was conducted by 
Kaplan–Meier survival curves and Log Rank test. All 
analyses were performed using SPSS Statistics version 
17.0 (SPSS Inc., Chicago, IL, USA). p values <0.05 were 
considered significant.
Results
Patients’ characteristics are listed in Table 1. Preoperative 
mean IIEF-5, IPSS and QoL scores were similar among 
the four groups. Nevertheless, other characteristics were 
different with statistical significance, indicating the dif-
ferent compositions.
Intergroup oncological outcome comparison is dem-
onstrated in Table  2. During similar mean follow-up 
duration of nearly 3 years, the patients of HDRBT dem-
onstrated higher PSA biochemical recurrence rate over-
all (54.7%), as well as D’Amico intermediate-risk (34.4%) 
and D’Amico high-risk (61.8%) groups than did patients 
of the other three treatments with statistical significance. 
Kaplan–Meier analysis for biochemical recurrence-free 
survival also revealed compatible results (Fig.  1). (Log 
Rank test: overall P = 0.000, D’Amico low-risk P = 0.689, 
intermediate-risk P = 0.043, high-risk P = 0.027). More-
over, the patients of HDRBT had significantly lower sal-
vage treatment-free rate (46.7%) and metastasis-free rate 
(90.7%) than did patients of the other three treatments.
Intergroup functional outcome comparison is reported 
in Table  3. In terms of postoperative complications, the 
patients of RRP had significantly higher rate of urethral 
stricture (29.9%), secondary TURP or OIU (28.9%), uri-
nary incontinence (11.3%) than did those of the other 
three treatments. Irradiation cystitis (3.7%) and irra-
diation proctitis (4.3%) were unique for the patients of 
HDRBT. Similarly, transient scrotal edema (74.7%) was 
common for the patients of cryoablation. Rectal injury 
was only seen in the patients of RRP (1.0%) and HDRBT 
(1.9%).
There were 38, 34, 50 and 32 patients of RRP, HDRBT, 
cryoablation and HIFU whose IIEF-5 score was ≥17 at 
baseline respectively. The mean preoperative IIEF-5 score 
of these patients was similar. The four groups of patients 
had a decline in IIEF-5 score postoperatively. However, 
the patients of HIFU experienced significantly lower 
postoperative erectile dysfunction rate at 12  months 
(65.6%, P = 0.042) and higher serial IIEF-5 score at 6, 12 
and 18 months than those of the other three treatments 
(Fig. 2).
The four groups of patients had similar preoperative 
IPSS and QoL scores. Postoperatively, all the four groups 
experienced decreased IPSS and QoL scores from base-
line, indicating improvement of urinary function. Post-
operatively, the patients of HIFU had significantly lower 
IPSS at 6, 12, and 18 months and lower QoL scores at 6 
and 12  months than did those of the other three treat-
ments (Figs. 3, 4).
Discussion
The dilemma between definitive treatment and obser-
vation/watchful waiting for localized prostate cancer is 
an important question without standard answer. In the 
PIVOT study, radical prostatectomy did not significantly 
reduce all-cause or prostate-cancer specific mortality, 
as compared with observation during at least 12  years 
of follow-up (Wilt et  al. 2012). In contrast, the SPCG-4 
study reported that radical prostatectomy significantly 
reduced all cause mortality by 12.7% (P  <  0.001) and 
prostate-cancer specific mortality by 11.0% (P  =  0.001) 
compared to watchful waiting during 23.2  years of fol-
low-up (Bill-Axelson et al. 2014). Besides, surgical treat-
ment for localized prostate cancer will inevitably result in 
complications and functional impairments. Therefore, an 
ideal treatment for localized prostate cancer with accept-
able cancer control and less complications can avoid not 
only overtreatment and negative impact on quality of life 
but also disease progression and anxiety related to obser-
vation/watchful waiting.
With regard to oncological outcome comparisons, the 
patients of HDRBT experienced the worst cancer control 
in PSA biochemical recurrence (overall, D’Amico inter-
mediate and high risk), salvage treatment-free rate and 
metastasis-free rate compared to those of the other three 
treatments. Even the patient distribution by D’Amico 
risk group is not equal in the four treatment modalities 
statistically, this result still reflects the insufficiency of 
pure HDRBT without androgen deprivation therapy for 
D’Amico intermediate and high-risk patients. Accord-
ing to NCCN guidelines and previous studies, neoad-
juvant/concomitant/adjuvant androgen deprivation 
therapy is suggested for intermediate-risk (4–6 months) 
and high-risk patients (2–3  years) (National Compre-
hensive Cancer N 2014; Zumsteg et al. 2013; Bolla et al. 
2010; D’Amico et al. 2008; Bolla et al. 2002). Our results 
are compatible with this suggestion. In the present study, 
cryoablation and HIFU demonstrated non-inferior onco-
logic outcomes to RRP, which is considered as standard 
treatment for localized prostate cancer. This intermedi-
ate-term result appears to be promising and needs fur-
ther follow-up.
In respect of postoperative complications, RRP resulted 
in more urinary incontinence (11.3%), urethral stric-
ture (29.9%) and secondary TURP or OIU (28.9%) than 
did the other three treatments. In the literature review, 
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post-RRP urinary incontinence rate decreased with time 
(49.5% at 3  months, 9.5% at 24  months). Finally, 1–3% 
patients needed surgical intervention (Namiki and Arai 
2010). Even in the era of robotic surgery, we still cannot 
find significant improvement of urinary incontinence rate 
after robotic-assisted laparoscopic radical prostatectomy 
compared with open radical prostatectomy (Haglind 
et  al. 2015). Although we may expect the possibly par-
tial recovery of urinary incontinence after a long time, 
post-RRP urinary incontinence is still a major concern 
for patients’ quality of life, especially for younger patients 
with longer life expectancy.
In terms of sexual function, the patients of HIFU dem-
onstrated significantly lower de novo erectile dysfunction 
Table 1 Patients’ characteristics
RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, SD standard deviation, iPSA initial 
prostate-specific antigen, IIEF-5 5-item version of the international index of erectile function, IPSS international prostate symptom score, QoL quality of life
a Mean scores for IIEF-5 were restricted to those men who reported IIEF-5 ≥ 17 at baseline
Variable RRP (N = 97) HDR (N = 161) Cryo (N = 114) HIFU (N = 120) P value
Age, years (mean ± SD) 63.53 ± 6.71 71.92 ± 7.03 69.76 ± 6.49 68.06 ± 1.91 0.000
Preoperative prostate volume, mL (mean ± SD) 37.71 ± 16.97 37.48 ± 18.58 36.71 ± 16.94 21.97 ± 10.90 0.000
 iPSA, ng/mL (mean ± SD) 16.08 ± 23.38 23.34 ± 20.40 26.76 ± 49.33 17.04 ± 21.88 0.002
 iPSA ≤ 10 ng/mL, N (%) 40 (41.2) 39 (24.2) 39 (34.2) 54 (45.0) 0.000
 iPSA 10–20 ng/mL, N (%) 37 (38.1) 46 (28.6) 39 (34.2) 38 (31.7)
 iPSA ≥ 20 ng/mL, N (%) 20 (20.6) 76 (47.2) 36 (31.6) 28 (23.3)
Gleason score 0.002
 ≤6, N (%) 38 (39.2) 82 (50.9) 41 (36.0) 36 (30.0)
 7, N (%) 41 (42.3) 45 (28.0) 38 (33.3) 57 (47.5)
 ≥8, N (%) 18 (18.6) 34 (21.1) 35 (30.7) 27 (22.5)
T stage 0.000
 <T2b, N (%) 16 (16.5) 26 (16.1) 52 (45.6) 73 (60.8)
 T2b, N (%) 7 (7.2) 34 (21.1) 16 (14.0) 14 (11.7)
 >T2b, N (%) 74 (76.3) 101 (62.7) 46 (40.4) 33 (27.5)
D’Amico risk group 0.000
 Low, N (%) 9 (9.3) 6 (3.7) 19 (16.7) 15 (12.5)
 Intermediate, N (%) 10 (10.3) 32 (20.0) 24 (21.1) 47 (39.2)
 High, N (%) 78 (80.4) 123 (76.4) 71 (62.3) 58 (48.3)
IIEF-5 ≥ 17, preoperative, N (%) 38 (39.2) 34 (21.1) 50 (43.9) 32 (26.7) 0.000
IIEF-5, preoperativea (mean ± SD) 23.61 ± 2.13 22.88 ± 1.81 22.96 ± 2.44 22.10 ± 2.62 0.054
IPSS, preoperative (mean ± SD) 11.64 ± 8.84 8.51 ± 7.73 11.73 ± 7.53 10.16 ± 7.24 0.100
QoL, preoperative (mean ± SD) 3.60 ± 1.96 3.06 ± 2.01 3.11 ± 1.74 2.91 ± 1.69 0.266
Table 2 Oncological outcome comparison
RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, SD standard deviation, PSA 
prostate-specific antigen
Variable RRP (N = 97) HDR (N = 161) Cryo (N = 114) HIFU (N = 120) P value
Follow-up duration, months (mean ± SD) 34.68 ± 12.45 33.54 ± 14.95 33.46 ± 14.38 32.68 ± 11.87 0.338
PSA nadir, ng/mL (mean ± SD) 0.40 ± 1.10 0.94 ± 1.59 0.81 ± 2.29 0.64 ± 1.77 0.031
PSA biochemical recurrence, N (%) 47 (48.5) 88 (54.7) 36 (31.6) 29 (24.2) 0.000
Low risk, N (%) 2 (22.2) 1 (16.7) 2 (10.5) 1 (6.7) 0.699
Intermediate risk, N (%) 3 (30.0) 11 (34.4) 3 (12.5) 4 (8.5) 0.020
High risk, N (%) 42 (53.8) 76 (61.8) 31 (43.7) 24 (41.4) 0.024
PSA biochemical recurrence-free survival, months (mean ± SD) 22.13 ± 14.85 21.17 ± 14.49 26.39 ± 12.53 27.66 ± 13.72 0.000
Salvage treatment free, N (%) 59 (60.8) 75 (46.7) 82 (71.9) 84 (70.0) 0.000
Metastasis free, N (%) 92 (94.8) 146 (90.7) 113 (99.1) 119 (99.2) 0.001
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rate at 12 months (65.5%) and higher serial IIEF-5 scores 
than did those of the other three treatments, indicating 
more possibility of sexual function preservation. In a pro-
spective study comparing radical prostatectomy, brachy-
therapy and cryoablation, brachytherapy led to better 
sexual function and bother scores than did radical pros-
tatectomy and cryoablation for 3  years (Malcolm et  al. 
2010). We did not see the trend in this study, probably 
due to significantly older age in the patients of HDRBT. 
Another prospective study revealed that patients of HIFU 
had continuously better postoperative IIEF scores than 
cryoablation for 3 years (Li et al. 2010). Our results were 
compatible with this finding. It is worth noting that the 
real serial IIEF-5 scores of RRP may be underestimated 
because the neurovascular bundle sparing technique 
was not intentionally used in this study. In a recent sys-
temic review, mean potency recovery rates at 12 months 
can reach 55–81% for patients treated with robotic-
assisted laparoscopic prostatectomy and 26–63% for 
patients treated with retropubic radical prostatectomy 
(Ficarra et al. 2012). Thus, the potency rate may increase 
with the improvement of surgical device and technique. 
Besides, the patients of HIFU experienced significantly 
lower serial IPSS and QoL scores than did those of the 
other three treatments, implying better urinary func-
tion improvement. The previous study comparing radical 
Fig. 1 Kaplan–Meier analysis for PSA biochemical recurrence-free survival among primary radical retropubic prostatectomy, high dose rate 
brachytherapy, cryoablation and high-intensity focused ultrasound a overall b D’Amico low risk c D’Amico intermediate risk d D’Amico high risk; 
RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, PSA prostate-
specific antigen
Page 6 of 8Chiang and Liu  SpringerPlus  (2016) 5:1905 
prostatectomy, brachytherapy and cryoablation reported 
that the patients of brachytherapy and cryotherapy had 
better urinary function and bother scores than those 
undergoing radical prostatectomy (Malcolm et al. 2010). 
These conclusions were similar to our results. To sum up, 
the outcomes for sexual and urinary function are con-
vincing and highlight that HIFU may be an alternative 
choice than the other three treatments with regard to 
quality of life.
In our experience, the delicate surgical margin is 
more easily to be controlled by HIFU because of the 
computer-programmed targeted area by 0.06  mL each 
time. Therefore, the precise “nerve-sparing” or focal 
HIFU decreases the erectile dysfunction rate to 22–31% 
and results in better sexual function preservation (Shoji 
et  al. 2010; Poissonnier et  al. 2007). Moreover, we rou-
tinely performed TURP before HIFU. The advantages of 
Table 3 Functional outcome comparison
RRP radical retropubic prostatectomy, HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity focused ultrasound, TURP transurethral resection of 
the prostate, OIU optic internal urethrotomy, SD standard deviation, IIEF-5 5-item version of the international index of erectile function, IPSS international prostate 
symptom score, QoL quality of life
a Erectile dysfunction and Mean scores for IIEF-5 were restricted to those men who reported IIEF-5 ≥ 17 at baseline
Variable RRP (N = 97) HDR (N = 161) Cryo (N = 114) HIFU (N = 120) P value
Urethral stricture, N (%) 29 (29.9) 10 (6.2) 4 (3.3) 13 (10.8) 0.000
Secondary TURP or OIU, N (%) 28 (28.9) 18 (11.2) 10 (8.8) 16 (13.3) 0.000
Urinary incontinence, N (%) 11 (11.3) 1 (0.6) 2 (1.6) 3 (2.5) 0.000
Epididymitis, N (%) 2 (2.1) 6 (3.7) 8 (7.3) 7 (5.8) 0.311
Scrotal edema, N (%) 0 (0.0) 0 (0.0) 85 (74.7) 0 (0.0) 0.000
Rectal injury, N (%) 1 (1.0) 3 (1.9) 0 (0.0) 0 (0.0) 0.243
Irradiation cystitis, N (%) 0 (0.0) 6 (3.7) 0 (0.0) 0 (0.0) 0.006
Irradiation proctitis, N (%) 0 (0.0) 7 (4.3) 0 (0.0) 0 (0.0) 0.002
Erectile dysfunction at 12 months, N (%)a 32/38 (84.2) 30/34 (88.2) 44/50 (88.0) 21/32 (65.6) 0.042
IIEF-5 at 6 months (mean ± SD)a 6.08 ± 6.27 4.85 ± 5.52 4.02 ± 5.95 8.55 ± 8.41 0.031
IIEF-5 at 12 months (mean ± SD)a 6.33 ± 6.06 4.81 ± 5.47 3.61 ± 5.21 9.67 ± 7.74 0.003
IIEF-5 at 18 months (mean ± SD)a 6.74 ± 6.07 4.79 ± 5.32 4.50 ± 5.96 10.16 ± 8.11 0.008
IIEF-5 at 24 months (mean ± SD)a 5.48 ± 5.28 4.76 ± 5.48 4.18 ± 5.89 9.36 ± 6.33 0.067
IPSS at 6 months (mean ± SD) 9.55 ± 6.11 7.51 ± 5.81 10.43 ± 6.50 7.26 ± 4.41 0.009
IPSS at 12 months (mean ± SD) 9.69 ± 6.01 7.48 ± 5.56 9.54 ± 5.87 6.25 ± 3.42 0.021
IPSS at 18 months (mean ± SD) 9.52 ± 6.05 7.49 ± 5.67 9.15 ± 6.08 5.82 ± 3.75 0.047
IPSS at 24 months (mean ± SD) 9.31 ± 5.83 7.50 ± 5.43 9.04 ± 6.30 5.70 ± 3.53 0.184
QoL at 6 months (mean ± SD) 2.50 ± 1.59 2.27 ± 1.33 2.75 ± 1.41 1.90 ± 0.14 0.017
QoL at 12 months (mean ± SD) 2.52 ± 1.57 2.30 ± 1.42 2.59 ± 1.42 1.83 ± 1.01 0.097
QoL at 18 months (mean ± SD) 2.45 ± 1.56 2.32 ± 1.28 2.5 ± 1.41 1.86 ± 1.17 0.318
QoL at 24 months (mean ± SD) 2.50 ± 1.65 2.33 ± 1.47 2.47 ± 1.40 1.98 ± 1.4 0.794
Fig. 2 Mean scores for IIEF-5 among primary radical retropubic 
prostatectomy, high dose rate brachytherapy, cryoablation and high-
intensity focused ultrasound; RRP radical retropubic prostatectomy, 
HDR high dose rate brachytherapy, Cryo cryoablation, HIFU high-
intensity focused ultrasound, IIEF-5 5-item version of the international 
index of erectile function; note: mean scores for IIEF-5 were restricted 
to those men who reported IIEF-5 ≥ 17 at baseline
Fig. 3 Mean scores for IPSS among primary radical retropubic prosta-
tectomy, high dose rate brachytherapy, cryoablation and high-inten-
sity focused ultrasound; RRP radical retropubic prostatectomy, HDR 
high dose rate brachytherapy, Cryo cryoablation, HIFU high-intensity 
focused ultrasound, IPSS international prostate symptom score
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TURP before HIFU are (1) to reduce the prostate volume, 
especially ventral, apical or intravesical prostate tissue 
to avoid incomplete treatment; (2) to remove prostatic 
calcification or abscess that would attenuate the HIFU 
energy; and (3) to reduce the postoperative obstruction 
complication rate (from 31 to 6%) (Poissonnier et  al. 
2007; Chaussy and Thuroff 2003; Netsch et al. 2010). In 
other words, TURP before HIFU is the key point for suc-
cessful oncological and functional outcomes.
Some limitations of this study should be noted. First, 
it was a retrospective and non-randomized study. There-
fore, the inclusion criteria of the four treatment modali-
ties cannot be defined clearly and the baseline data for 
the four groups cannot be totally equal. In fact, it is dif-
ficult to conduct a randomized controlled trial for sur-
gical devices in the real world. It is a matter of patients’ 
performance, preference, medical cost and clinicians’ 
experience. Though the patients’ characteristics have sta-
tistically significant differences in each group, we com-
pare the PSA biochemical recurrence rate in D’Amico 
low, intermediate and high risk group respectively, 
according to initial PSA, clinical stage and Gleason score. 
This kind of comparison may be more objective and alle-
viate the patient selection bias. In addition, the mean fol-
low-up duration of nearly 3  years was relatively shorter 
for oncological outcomes. However, it may be sufficient 
for evaluation of the functional outcomes in accord-
ance with previous studies. Finally, postoperative sexual 
function of patients undergoing RRP should be carefully 
interpreted due to lack of neurovascular bundle sparing 
technique in this study.
To the best of our knowledge, it is the first single 
institutional and comparative study discussing com-
parison of the oncological and functional outcomes of 
radical retropubic prostatectomy, high dose rate brachy-
therapy, cryoablation and high-intensity focused ultra-
sound for localized prostate cancer. Besides, there is no 
inter-institutional and inter-operator bias in this study 
because except for radiation oncologists, almost all 
patients undergoing these four treatments (radical retro-
pubic prostatectomy, high dose rate brachytherapy, cry-
oablation and HIFU) had them performed by the same 
surgeon (Dr. Po Hui Chiang). Moreover, this study will 
provide useful information and give rise to the interest of 
urological oncologists. We look forward to further pro-
spective, randomized controlled trials in the treatment of 
localized prostate cancer in the future.
Conclusion
Among the four treatments, the patients of high dose rate 
brachytherapy demonstrated the worst oncological out-
comes, especially in D’Amico intermediate- and high-risk 
groups. Besides, the patients of radical retropubic pros-
tatectomy had more complications rate in urethral stric-
ture and urinary incontinence. Moreover, the patients of 
HIFU experienced better urinary function improvement 
and more possible sexual function preservation. In con-
sideration of trifecta, HIFU may provide equivalent can-
cer control in the intermediate-term follow-up and better 
quality of life for patients of localized prostate cancer.
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